Canadian Post-doctoral Fellowships Awarded in type 1 diabetes Research

Lilly Canada provided JDRF with $220,000 in 2013-2014 in support of the creation of a national clinical training program to enable young investigators to further engage in medical research associated with type 1 diabetes.

The program operates through the JDRF Canadian Clinical Trial Network (CCTN), a consortium of Canadian investigators and institutions collaborating to conduct research and clinical trials related to type 1 diabetes.

During the past two years, as a result of their assessment of submitted proposals, JDRF has selected the following five postdoctoral fellows as recipients each of a one-year grant allowing them to participate in unique training opportunities in type 1 translational and clinical research:

2013 Recipients:

Investigator:

Emmeline Heffernan, MB, BCh, BAO

Institution:

Children’s Hospital of Eastern Ontario, Ottawa, ON Canada

Project:

Evaluation of a novel CGM trend arrow bolus adjustment tool in children and adolescents with type 1 diabetes using insulin pump therapy and continuous glucose monitoring


 

Description: A novel bolus adjustment tool was developed specifically for the JDRF CCTN sponsored CGM TIME Trial (Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes.) This study will evaluate the Trend Arrow Adjustment Tool to determine its effectiveness in reducing postprandial hyper- and hypoglycaemia, as well as parent, child/youth satisfaction, and ease of use of the tool based on self-report measures.

*This award is made possible through a partnership with JDRF-UK, with special thanks to the Gillespie Family

Investigator:

Ashish Marwaha, MBBCh

Institution:

University of British Columbia, Vancouver, BC Canada

Project:

Management of clinical trial of ustekinumab in new-onset type 1 diabetes


 

Description: This pilot clinical trial will test the safety of a biologic drug, ustekinumab, in adult subjects with recent-onset T1D. Ustekinumab is currently used in the treatment of psoriasis.    

2014 Recipients:

Investigator:

Alexandra Paun, PhD

Institution:

Hospital for Sick Children, Toronto, ON Canada

Project:

Immune responses to gut microbiome during progression of islet autoimmunity

Description: There is growing evidence that variation in the human community of the gut microbiome contributes to metabolic and inflammatory diseases, and is associated with risk for development of T1D. Ultimately, it is hoped that this research will help guide preventive therapies targeting the gut microbiome compositing in individuals at risk.

Investigator:

Andrew Pepper, PhD

Institution:  

University of Alberta, Edmonton, AB Canada

Project:

Synergizing novel cell death inhibitors to promote indefinite insulin independence post-single donor islet transplantation

Description: This work aims to improve the safety and efficiency of clinical islet transplantation, provide a unique opportunity to develop minimal immunosuppressive approaches, and open up an accelerated avenue for future clinical evaluation of catalytic antioxidants to abrogate disease progression in early onset T1D.

Investigator:  

Alanna Weisman, MD

Institution:

Mount Sinai Hospital, Toronto, ON, Canada

Project:

Canadian study of longevity in diabetes: Discovering factors for success after 50 years of type 1 diabetes

Description: This study observes a collection of people with T1D who have had the disease for 50 years or more without significant complications. Understanding how these people differ from those who get significant complications in the same time span will help to define protective factors or types of treatment that lead to protection from complications.

Lilly Canada and the JDRF CCTN will grant two additional fellowships in 2015.

For more information, please visit jdrf.ca/cctn.


About JDRF Canada

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries.  For more information, please visit jdrf.ca.

Lets turn type one into type none